文献速递血栓与止血

携带CYP2C9和VKORC1变异的老年患者接受维生素K拮抗剂治疗的长期结局

Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
PubMed 文献 · J Thromb Haemost · 2017-09-25

这项前瞻性队列研究随访了9家瑞士医院的774例≥65岁急性静脉血栓栓塞症患者,中位随访30个月。604例(78%)携带CYP2C9或VKORC1变异。校正后,CYP2C9变异与任何临床事件(HR 1.34;95%CI 1.08-1.66)、死亡(HR 1.74;95%CI 1.19-2.52)和临床相关非大出血(SHR 1.39;95%CI 1.02-1.89)相关,与大出血和复发VTE无关。

要点

  • CYP2C9变异与死亡风险升高相关(HR 1.74;95%CI 1.19-2.52)。
  • CYP2C9变异与临床相关非大出血风险升高相关(SHR 1.39;95%CI 1.02-1.89)。
  • 遗传变异仅与略低的抗凝质量相关,与大出血或复发VTE无关。

核心结论

  • CYP2C9变异与长期全因死亡和非大出血相关;遗传变异与略低的抗凝质量相关,但与大出血或VTE复发无关。

研究设计与样本

  • 前瞻性队列研究,纳入9家瑞士医院的774例≥65岁急性VTE连续患者,中位随访30个月,初始抗凝中位疗程9.4个月。

主要发现

  • 604例(78%)患者携带CYP2C9或VKORC1变异;334例(43.2%)发生任何临床事件,119例(15.4%)死亡,100例(12.9%)发生大出血,167例(21.6%)发生非大出血,100例(12.9%)复发VTE。
  • 校正后CYP2C9变异与任何临床事件相关(HR 1.34;95%CI 1.08-1.66),VKORC1变异无此关联。
  • 校正后CYP2C9变异与死亡相关(HR 1.74;95%CI 1.19-2.52)。
  • 校正后CYP2C9变异与临床相关非大出血相关(SHR 1.39;95%CI 1.02-1.89)。
  • 校正后CYP2C9变异与大出血(SHR 1.03;95%CI 0.69-1.55)和复发VTE(SHR 0.95;95%CI 0.62-1.44)无显著关联。

关键数值与推荐

  • 携带遗传变异患者的抗凝质量略低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The long-term effects of VKORC1 and CYP2C9 variants on clinical outcomes remains unclear. We followed 774 patients ≥65 years with venous thromboembolism for a median duration of 30 months. Patients with CYP2C9 variants are at increased risk of death and non-major bleeding. Patients with genetic variants have a slightly lower anticoagulation quality only. SUMMARY: Background The long-term effect of polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes remains unclear. Objectives We examined the association between CYP2C9/VKORC1 variants and long-term clinical outcomes in a prospective cohort study of elderly patients treated with vitamin K antagonists for venous thromboembolism (VTE). Methods We followed 774 consecutive patients aged ≥ 65 years with acute VTE from nine Swiss hospitals for a median duration of 30 months. The median duration of initial anticoagulant treatment was 9.4 months. The primary outcome was the time to any clinical event (i.e. the composite endpoint of overall mortality, major and non-major bleeding, and recurrent VTE. Results Overall, 604 (78%) patients had a CYP2C9 or VKORC1 variant. Three hundred and thirty-four patients (43.2%) had any clinical event, 119 (15.4%) died, 100 (12.9%) had major and 167 (21.6%) non-major bleeding, and 100 had (12.9%) recurrent VTE. After adjustment, CYP2C9 (but not VKORC1) variants were associated with any clinical event (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.08-1.66), death (HR, 1.74; 95% CI, 1.19-2.52) and clinically relevant non-major bleeding (sub-hazard ratio [SHR], 1.39; 95% CI, 1.02-1.89), but not with major bleeding (SHR, 1.03; 95% CI, 0.69-1.55) or recurrent VTE (SHR, 0.95; 95% CI, 0.62-1.44). Patients with genetic variants had a slightly lower anticoagulation quality. Conclusions CYP2C9 was associated with long-term overall mortality and non-major bleeding. Although genetic variants were associated with a slightly lower anticoagulation quality, there was no relationship between genetic variants and major bleeding or VTE recurrence.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nagler M, Angelillo-Scherrer A, Méan M, et al. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. J Thromb Haemost. 2017. PMID: 28834238. doi:10.1111/jth.13810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。